Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy? Commentary Journal Article

  

Authors:	Lassman, A. B.; Abrey, L. E.
Article Title:	Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy? Commentary
Keywords:	gene deletion; clinical trial; disease course; drug efficacy; drug withdrawal; unspecified side effect; adjuvant therapy; temozolomide; outcome assessment; follow up; computer assisted tomography; multiple cycle treatment; blood toxicity; clinical assessment; vincristine; lomustine; procarbazine; intermethod comparison; short survey; oligodendroglioma; heterozygosity loss; functional magnetic resonance imaging; drug substitution; astrocytoma; anaplastic carcinoma; neurologic examination; chromosome 1p; chromosome 19q
Journal Title:	Nature Clinical Practice Oncology
Volume:	4
Issue:	2
ISSN:	1743-4254
Publisher:	Nature Publishing Group
Date Published:	2007-02-01
Start Page:	78
End Page:	79
Language:	English
DOI:	10.1038/ncponc0690
PROVIDER:	scopus
PUBMED:	17228307
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-33846663893&partnerID=40&md5=e7e686d420b9f7d9bc5308ff434cc7a8
Notes:	--- - "Export Date: 17 November 2011" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/17689